ofa tirzepatide FDA approves to treat sleep apnea Tirzepatide for Medical Weight Loss

After announcing the state would initiate coverage of GLP-1s to combat obesity in September 2022 as part of their state employee health plan, the state reversed course and in January 2025 announced it was opting to end that coverage beginning July 1, 2025

JJ My name is Dr

They have come into the limelight after a large double-blinded study published in NEJM, showed an average 14.9% decrease in weight in obese patients given semaglutide on top of lifestyle modifications, compared to 2.4% in the control arm (see research summary at end)

Bottom Line For people with diabetes who also have celiac disease, a gluten-free diet is medically necessary

Paling I, Macintyre L